Establishing a Controlled Human Infection Model of Bordetella Pertussis

Open-label, Phase 1, Dose-escalation Clinical Trial to Establish a Controlled Human Infection Model by Determining the Optimal and Safe Bordetella Pertussis Dose That Induces Mild Symptomatic Infection and Colonization in Healthy Adults

This study aims to establish a Controlled Human Infection Model of Bordetella pertussis by determining a reproducible and safe infectious bacterial dose (challenge inoculum) that achieves colonization and mild symptomatic infection in healthy adults.

Study Overview

• Status: Recruiting
• Conditions: Pertussis
• Intervention / Treatment: Biological: Bordetella pertussis D420

Detailed Description

This is a single-center trial to develop a Bordetella pertussis Controlled Human Infection Model (CHIM) using a two-study approach: the first study is a human infectious dose 70%-90% (HID70-90) identification study, and the second an HID70-90 dose confirmation study to verify and confirm that the infectious endpoint has been reached. The infectious endpoint is positive nasopharyngeal culture(s) and/or polymerase chain reaction(s) (PCR(s)) for B. pertussis with concurrent or subsequent development of mild pertussis disease symptoms such as rhinorrhea and cough within the 16-day inpatient period following challenge.

The trial is an open-label, phase 1, dose escalation, self-contained trial; participants will be allocated to challenge dose groups to receive a single intranasal dose of challenge inoculum. All participants will receive a 5-day course of azithromycin eradication therapy either 24-48 hours after they develop symptoms or at the end of the 16-day postchallenge observation period.

The optimal/target inoculum is one that induces mild symptomatic infection and detection of B. pertussis in nasopharyngeal cultures in 70%-90% of participants receiving it, to establish a safe and reproducible pertussis CHIM.

Safety monitoring includes close clinical observation during a 16-21-day inpatient postchallenge period in the Canadian Center for Vaccinology's Challenge Unit, a Data and Safety Monitoring Board, and participant Diary Cards.

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Kylie Peacock; Phone Number: 902-470-8141; Email: kylie.peacock@iwk.nshealth.ca

Study Locations

• Canada
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3K 6R8
      • Recruiting
      • Canadian Center for Vaccinology
      • Principal Investigator: Scott A. Halperin, MD
      • Sub-Investigator: Joanne M. Langley, MD, MSc
      • Sub-Investigator: Jeannette L. Comeau, MD
      • Sub-Investigator: Shelly A. McNeil, MD
      • Sub-Investigator: May ElSherif, MBBS, MSc
      • Contact: Kylie Peacock; Phone Number: 902-470-8141; Email: kylie.peacock@iwk.nshealth.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

To be eligible for the study, each participant must satisfy ALL of the following criteria:

1. Age 18-40 years, inclusive.
2. Good general health status, as determined by history and physical examination conducted no longer than 30 days prior to the challenge.
3. Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., complete Diary Cards, return for follow-up visits).
4. Written informed consent obtained from the participant.

5. If female of childbearing potential and heterosexually active, has practiced adequate contraception for 28 days prior to challenge and has a negative pregnancy test on the day before B. pertussis challenge and has agreed to continue adequate contraception until 60 days after inoculation. Adequate contraception is defined as a contraceptive method with a failure rate of <1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:

   • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
   • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
   • Intra-uterine device (IUD) with or without hormonal release
   • Vasectomized partner, provided that this is the participant's sole partner and that he has received a medical assessment of the surgical success
   • Credible self-reported history of heterosexual abstinence for at least 28 days prior to challenge
   • Female partner

   A premenopausal woman who has at least one of the following is considered not of childbearing potential:

   • Documented hysterectomy
   • Documented bilateral salpingectomy
   • Documented bilateral oophorectomy
   • Documented and current bilateral tubal ligation or occlusion
6. Currently fully vaccinated against SARS-CoV-2/COVID-19 according to provincial Public Health guidelines.
7. If there is a reported history of SARS-CoV-2/COVID-19 infection, the participant must be asymptomatic for >4 weeks.

Exclusion Criteria:

Participants with ANY of the following criteria at the time of screening will be excluded:

1. Underlying chronic medical condition requiring ongoing follow-up and monitoring by a physician (e.g., diabetes, seizure disorder).
2. Underlying cardiac and/or pulmonary disease including hypertension, angina, prior myocardial infarction, asthma, emphysema, chronic bronchitis, and pulmonary tuberculosis.
3. Moderate or severe symptoms of health anxiety, anxiety, and mood symptoms. Self-reported current diagnosis of a major psychiatric illness, including a schizophrenia spectrum disorder, bipolar disorder, posttraumatic stress disorder, obsessive compulsive disorder, substance use, or eating disorder.
4. QT prolongation on electrocardiogram (EKG).
5. History of everyday smoking/vaping in the last 2 years and/or current smoking/vaping more than once per week.
6. Pregnant (known before or established at the time of screening using a urine-based test) or breastfeeding.
7. Immunocompromised (with HIV/AIDS-positive or receiving immunosuppressive therapy involving steroids) or with any medical condition or medication that leads to a compromised immune system.
8. Positive for hepatitis B or C.
9. Vaccinated against pertussis within previous 5 years and/or >7 cumulative doses from infancy to date of screening.
10. Reported history of laboratory-confirmed pertussis infection.
11. Antibody titer to pertussis toxin >20 EU/mL (2x the lower limit of quantification (LLOQ)).
12. Nasopharyngeal detection of B. pertussis prior to challenge using culture isolation and/or PCR detection, or detection of other respiratory infection.
13. Living with young children (<1 year of age) or with any household member not current in their pertussis immunization. Note: Household members whose vaccination is not current will be offered a pertussis-containing vaccine, as recommended and funded by the Nova Scotia Department of Health and Wellness.
14. Living or working with (any form of close contact) any of the at-risk/vulnerable groups (children <1 year of age, pregnant woman who have not yet received their maternal Tdap vaccine, immunocompromised individuals, anyone not current in their pertussis immunization, or adults >65 years of age who have not received a dose of Tdap vaccine within the past 10 years).
15. Known allergy to macrolides including azithromycin or erythromycin, history of Clostridium difficile within last 2 months.
16. Any contraindication to receiving azithromycin.
17. Taking any antibiotic currently or within the previous 2 weeks.
18. Currently taking terfenadine, astemizole, theophylline, or cimetidine.
19. Recent (within 6 months) nasal or sinus surgery, recent use of intranasal steroids (4 weeks), or diagnosis with nasal polyps.
20. Receipt of any investigational drug or vaccine (including SARS-CoV-2/COVID-19 vaccine) within 6 months prior to challenge. An investigational vaccine is defined as a vaccine that is still being tested in clinical trials or one that has not yet been authorized for use in Canada for administration by public vaccine programs.
21. Receipt of any authorized vaccines within 2 weeks of being challenged with B. pertussis in this study. (This is to avoid attributing any AEs from these vaccines to the B. pertussis challenge, which would skew the study results.)
22. Current laboratory-confirmed SARS-CoV-2/COVID-19 infection.
23. Previous moderate or severe laboratory-confirmed SARS-CoV-2/COVID-19 infection that required hospitalization.
24. Head trauma (e.g., fracture of the cribriform plate) within 1 year of screening.
25. Any other finding that the Investigator considers will make the participant unsuitable for the study or unable to comply with the study requirements.
26. Symptoms indicative of acute respiratory illness (such as fever, cough, difficulty breathing) identified during the physical examination done on Day -1 (check-in) or Day 0 before a participant is challenged.
27. History of Bell's Palsy and/or facial paralysis.
28. Receipt of facial cosmetic filler in the past 3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Study 1 (Dose-identification study), Dose 1; Challenge dose of 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 2; Challenge dose of 5 x 10^3 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 3; Challenge dose of 10^4 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 4; Challenge dose of 5 x 10^4 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 5; Challenge dose of 10^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 6; Challenge dose of 5 x 10^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 7; Challenge dose of 10^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 8; Challenge dose of 5 x 10^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 9; Challenge dose of 10^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
Experimental: Study 1 (Dose-identification study), Dose 10; Challenge dose of 5 x 10^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)	Biological: Bordetella pertussis D420; Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with mild symptoms of early pertussis disease postchallenge	Mild, Grade 1, symptoms of pertussis are symptoms that do not interfere with everyday activities. They may include malaise, rhinorrhea, sneezing and/or lacrimation, low-grade fever, or cough.	Day 0 (challenge day) to Day 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants who demonstrate shedding of Bordetella pertussis postchallenge as determined by positive culture and/or PCR test of nasopharyngeal samples	The presence of B. pertussis is detected by positive culture (i.e., presence of any B. pertussis colonies) of nasopharyngeal samples. It is also detected by a positive PCR (polymerase chain reaction) test of nasopharyngeal samples. Both methods are used in this study; a positive result in either culture and/or PCR test demonstrates shedding of B. pertussis.	Day 1 to Day 14

Collaborators and Investigators

• Sponsor: Dalhousie University
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); Vanderbilt University Medical Center; Centers for Disease Control and Prevention
• Investigators: Principal Investigator: Scott A. Halperin, MD, Dalhousie University

Publications and helpful links

Helpful Links

• Canadian Center for Vaccinology home page
• Canadian Center for Vaccinology Challenge Unit home page

Study record dates

Study Major Dates

• Study Start (Actual): January 28, 2022
• Primary Completion (Estimated): January 1, 2024
• Study Completion (Estimated): January 1, 2025

Study Registration Dates

• First Submitted: November 2, 2021
• First Submitted That Met QC Criteria: November 15, 2021
• First Posted (Actual): November 29, 2021

Study Record Updates

• Last Update Posted (Actual): June 23, 2023
• Last Update Submitted That Met QC Criteria: June 21, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: Phase 1 clinical trial; Pertussis; Immune response; Whooping cough; Bordetella pertussis; Controlled human infection model; Human challenge
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Respiratory Tract Diseases; Bordetella Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Whooping Cough
• Other Study ID Numbers: CD2001; R34AI148056 (U.S. NIH Grant/Contract); 75D30120C08608 (Other Grant/Funding Number: Centers for Disease Control and Prevention)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No